Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Fig. 3

In vivo safety profile of TEG001. (a) Schematic overview of the safety experiment in healthy donor-derived xenograft (H-DX) model. NSG mice were irradiated at day 0 and engrafted with healthy cord blood-derived CD34+ progenitor cells on day 1. Engraftment was followed-up in peripheral blood by flow cytometry and when > 500 huCD45+ cells/ml were present, mice received 2 injections of therapeutic TEG001 or TEG-LM1 mock in the presence of PAM (at week 6 and 8) and IL-2 (at week 6); (b-c) In vivo safety profile of TEG001 towards healthy human hematopoietic cells. Healthy human cells engrafted in NSG mice (b) with long-term persistence of TEGs in peripheral blood (c). Data represent mean ± SD of all mice per group (n = 10)

Back to article page